GE Healthcare has received FDA pre-market approval (PMA) for its End-tidal (Et) Control software for general anaesthesia delivery on its Aisys CS2Anesthesia Delivery System.
GE Healthcare is the only manufacturer approved to offer general anaesthesia delivery with end-tidal concentration control in the US.
The company initially released the technology in Europe in 2010 and today, anaesthesia providers use Et Control software to care for patients in over 100 countries.
Each year more than 300 million patients worldwide undergo surgical procedures, many of them requiring general anaesthesia utilizing inhaled anesthetic agents at a cost of $1.2 billion annually.
The Et Control software semi-automates the delivery of anaesthesia using software, allowing anaesthesia providers to set targets for end-tidal oxygen and anaesthetic agent.
Once targets are set, the software quickly achieves and maintains those targets, regardless of changes in the patient's hemodynamic and metabolic status. The Et Control software improves anaesthesia delivery accuracy and simplifies workflows while reducing drug waste, lowering the cost of care and greenhouse gas emissions.
- A potential 44% decline in greenhouse gas emissions due to more efficient use of anaesthetic agents
- Increased accuracy in maintaining the target concentrations of oxygen and anaesthetic agents
- 50% reduction in manual keystrokes, helping providers spend less time making adjustments and more time observing the patient
- A potential 27% reduction in operating room costs due to lower anaesthetic agent spend through the reduction of anaesthetic agent waste
“In the past, we continually adjusted vaporizer setting and fresh gas flow to control inspired concentration in an attempt to achieve and maintain the end-tidal concentration we wanted for our patients.
“To have direct control of the end-tidal concentration that reflects the drug level in the patient’s blood is a big step forward for our ability to personalize a patient’s care. Additionally, low-flow anaesthesia has benefits for hospitals and the environment,” said Dr Jim Philip, Anesthesiologist and Director of Clinical Bioengineering, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital.
Dr Philip, who has been a leading proponent for approval of automated control of inhalation drug administration for years, has also served as a paid consultant for GE Healthcare from April 2020 to December 2021.
“Anaesthesia providers in the US will have access to the most advanced anaesthesia tools available to improve patient care,” said Eric Ruedinger, General Manager of GE Healthcare’s Anesthesia and Respiratory Care business.
“As the long-standing global leader in anaesthesia delivery, GE Healthcare invested in the development and clinical validation of this Et Control algorithm, and we are committed to creating clinically relevant solutions that will enhance anaesthesia practices into the future.”
The FDA approval was supported by the results from the US-based, multi-centre, multi-year MASTER-Anesthesia Trial – with over 200 patients (18 years of age and older) enrolled.
The trial evaluated the safety and effectiveness of the Et Control software versus conventional anaesthetic gas delivery methods during general anaesthesia. With this FDA approval, GE Healthcare will launch the Aisys CS2Anesthesia Delivery System with Et Control in the U.S in the coming months.
For more information, visit www.gehealthcare.com/etc.
